| Bioactivity | CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity[1]. CGP 39551 shows measurable inhibitory activity at both L-[3H]-glutamate (Ki=8.4 μM)[2]. |
| Invitro | CGP 39551 inhibits the binding of the selective NMDA receptor antagonist, [3H]-CPP to rat brain postsynaptic densities (PSDs) with a Ki of 310 nM[2]. |
| In Vivo | CGP 39551 exhibits maximal electroshock-induced seizures in mice with the ED50 of 4 mg/kg (p.o.)[2].Following chronic neonatal treatment with CGP 39551, adult rats show increased behavioral responses to the D2 dopamine receptor stimulation[3]. |
| Name | CGP 39551 |
| CAS | 127910-32-1 |
| Formula | C8H16NO5P |
| Molar Mass | 237.19 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. G E Fagg,et al. CGP 37849 and CGP 39551: novel competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity. Prog Clin Biol Res. 1990;361:421-7. [2]. G E Fagg, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol. 1990 Apr;99(4):791-7. [3]. R Dall'Olio, et al. Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat. Neuroscience. 1994 Nov;63(2):451-5. |